

Cynata Therapeutics Receives Notice of Allowance from Israel Patent Office for Cymerus™ Patent Application

Melbourne, Australia; 6 February 2020: Australian stem cell and regenerative medicine company, Cynata Therapeutics Limited (ASX: CYP or “the Company”), announced today that a Notice of Allowance has been received from the Israel Patent Office (ILPO) for a patent application covering its proprietary Cymerus™ mesenchymal stem cell technology. The patent application entitled “Methods and materials for hematoendothelial differentiation of human pluripotent stem cells under defined conditions” is owned by the University of Wisconsin–Madison’s Wisconsin Alumni Research Foundation (WARF) and is among the intellectual property licensed exclusively from WARF to Cynata.

The Notice of Allowance is sent to the applicant when the ILPO intends to issue a patent. The patent will extend the already strong IP protection of the Cymerus platform and its unique ability to manufacture mesenchymal stem cells (MSCs) at scale, from a single donation, to create therapeutic stem cell products.

“Our broad and comprehensive patent portfolio continues to grow as we further strengthen our unique and proprietary IP around the Cymerus technology,” said Dr Ross Macdonald, Cynata’s Chief Executive Officer. “The ability of the Cymerus platform to enable manufacture of consistent, high-quality mesenchymal stem cells at scale is key to the ongoing development of off-the-shelf therapeutic stem cell products to target a range of devastating diseases worldwide.”

The inventors named on the patent are Professor Igor Slukvin, founder, advisor and shareholder of Cynata, and Dr Gene Uenishi.

Cynata anticipates that the patent will be granted around mid-April 2020, with an expiration date of 12 March 2034.

-ENDS-

Authorised for release by Dr Ross Macdonald, Managing Director & CEO

CONTACTS: Dr Ross Macdonald, CEO, Cynata Therapeutics, +61 (0)412 119343, ross.macdonald@cynata.com
Claire LaCagnina, U.S. Media Contact, +1 315.765.1462, clacagnina@6degreespr.com

About Cynata Therapeutics (ASX: CYP)

Cynata Therapeutics Limited (ASX: CYP) is an Australian clinical-stage stem cell and regenerative medicine company focused on the development of therapies based on Cymerus™, a proprietary therapeutic stem cell platform technology. Cymerus overcomes the challenges of other production methods by using induced pluripotent stem cells (iPSCs) and a precursor cell known as mesenchymoangioblast (MCA) to achieve economic manufacture of cell therapy products, including mesenchymal stem cells (MSCs), at commercial scale without the limitation of multiple donors.



Cynata's lead product candidate CYP-001 met all clinical endpoints and demonstrated positive safety and efficacy data for the treatment of steroid-resistant acute graft-versus-host disease (GvHD) in a Phase 1 trial. Cynata plans to advance its Cymerus™ MSCs into Phase 2 trials for GvHD, critical limb ischemia and osteoarthritis. In addition, Cynata has demonstrated utility of its Cymerus MSC technology in preclinical models of asthma, diabetic wounds, heart attack and cytokine release syndrome, a life-threatening condition stemming from cancer immunotherapy.